We could not find any results for:
Make sure your spelling is correct or try broadening your search.
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alte... CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California. Show more
- 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H’25 - - IND application for...
SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative...
- 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 - - CRG-023 pre-clinical data to be...
SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.7 | -17.9521276596 | 15.04 | 15.745 | 12.15 | 245182 | 14.05690702 | CS |
4 | -1.31 | -9.59706959707 | 13.65 | 15.83 | 12.15 | 296271 | 14.36677142 | CS |
12 | -9.66 | -43.9090909091 | 22 | 23 | 12.15 | 226515 | 16.55582551 | CS |
26 | -5.55 | -31.0229178312 | 17.89 | 25.45 | 12.15 | 276806 | 18.36395498 | CS |
52 | -7.55 | -37.9587732529 | 19.89 | 33.92 | 12.15 | 260600 | 20.5245866 | CS |
156 | -3.11 | -20.1294498382 | 15.45 | 33.92 | 12.15 | 254270 | 20.16380158 | CS |
260 | -3.11 | -20.1294498382 | 15.45 | 33.92 | 12.15 | 254270 | 20.16380158 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions